Sandoz, a Novartis division and the global leader in biosimilars, announced that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in Binocrit’s® (epoetin alfa) nephrology indication.
Carol Lynch, Global Head Biopharmaceuticals, Sandoz said, By expanding our biosimilar offering to the healthcare community, the EC approval of a subcutaneous route of administration for use in our Binocrit’s nephrology indication will mean more choice for healthcare professionals as well as increased convenience for patients.
